CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 188 enrolled
Drug / intervention
OMNYPULSE Bi-Directional Catheter with TRUPULSE Generatordevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05971693
NCT05971693N/ACompleted

Safety and Effectiveness Evaluation of the OMNYPULSE Catheter With the TRUPULSE Generator for Treatment of Paroxysmal Atrial Fibrillation (PAF)

Biosense Webster, Inc.·interventional·Posted Aug 2, 2023·Updated Mar 25, 2026

In Brief

A clinical study evaluating OMNYPULSE Bi-Directional Catheter with TRUPULSE Generator for Atrial Fibrillation. Completed, enrolled 188 participants across 13 sites in 8 countries.

Detailed Summary

The purpose of this study is to demonstrate safety and effectiveness of the ablation system (OMNYPULSE Bi-directional catheter and TRUPULSE generator) when used for isolation of the atrial pulmonary veins (PVs) in treatment of participants with paroxysmal atrial fibrillation (PAF).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesBelgium, Canada, Croatia, Czechia, Germany, Italy, Lithuania, Netherlands
Collaborators--

Timeline

N/ACompletedFinished
202420252026
First PostedAug 2, 2023
Enrollment StartSep 12, 2023
Primary CompletionDec 10, 2024
Study CompletionSep 5, 2025
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 2.9 years ago

Interventions

OMNYPULSE Bi-Directional Catheter with TRUPULSE Generatordevice

Participants will undergo catheter ablation with the PF ablation system consisting of the TRUPULSE generator (delivers PF energy through the study catheter) and the OMNYPULSE bi-directional catheter (indicated for use in catheter-based cardiac electrophysiological mapping \[stimulating and recording\] and, when used with a Generator, for cardiac ablation).